• PTC Therapeutics Executive VP and CLO Mark Elliott Boulding exercised stock options for 192 shares at $39.42 on Oct. 9, 2026.
• He sold 192 shares the same day at a weighted average price of $64.26.
• Directly held common stock totaled 105,272 shares following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001578852-26-000026), on October 13, 2026, and is solely responsible for the information contained therein.